Biotie and Seikagaku part ways
This article was originally published in Scrip
Executive Summary
Finnish firm Biotie Therapies and Seikagaku of Japan are terminating their licence agreement for Biotie's VAP-1 antibody programme. The licence, under which Biotie had granted Seikagaku exclusive rights for development and commercialisation of the VAP-1 monoclonal antibody BTT-1023 in Japan, Taiwan, Singapore, New Zealand and Australia, was signed in April 2003 and was built around Seikagaku's expertise in locomotive diseases such as osteoarthritis.